Yahoo Finance

The effects of these initiatives for employees, residents and patients are already evident:

• a decline in the work-related accident frequency rate to 24.8 in 2023 (down 2 points vs. 2022 and down 8 points vs. 2021);

• 72% of facilities now have a trained ethics and positive treatment correspondent, vs. 45% in 2022;

• a satisfaction rate of 92.5% (vs. 90.1% in 2022).

The significant improvements in our non-financial indicators underline the acceleration of our Group's transformation.

These measures are being put into practice as part of the "CREATE" programme, which is structured around the Group’s strategic priorities: our teams, patients, residents, and their relatives.

This programme comprises 48 cross-cutting projects co-constructed with the host countries and business lines, and comprises actions designed to give a major boost to operating performance. The initiatives include the segmentation of our offering and the overhaul of purchasing processes which, together with the whole program, are intended to have a positive €35 million to €40 million impact on EBITDAR in 2024.

In 2023, the operating performance continued to be affected by the inflationary context and the Group's transformation efforts. However, the sequential growth in the operating margin rate observed between the first and second halves of 2023 is evidence of the Group's positive momentum. The improvement in operating performance is set to continue into 2024, with EBITDAR expected to grow by between 15% and 20%.

Another key step in the Refoundation Plan has been the unveiling on 20 March of our new identity, emeis, and our corporate purpose: "Together, let’s stand as a strength for the vulnerable among us". This new identity embodies an ambitious corporate project to provide personalised care and support for all vulnerable people and represents the ambition of a Group that is transforming itself to better support the major societal challenges of mental and physical health, and old age. Building on these strengths, the Group is looking to the future with confidence and determination and is embarking on a transition to a mission-led business model by 2025, an initiative which will be put to the vote at the Annual General Meeting."

PUTEAUX, France, April 17, 2024--(BUSINESS WIRE)--Regulatory News:

ORPEA (Paris:ORP) :

ORPEA SA publishes its consolidated results for the year ended 31 December 2023¹, which were adopted by the Board of Directors on 16 April 2024.

Revenue saw sustained growth in 2023 (+11% vs. 2022, of which 9.5% organic growth), driven by an overall improvement in the occupancy rate and the opening of 31 new facilities.

Operating profitability continued to be affected by the newly implemented care and support measures, persistently high inflation in 2023 which could not be passed on through pricing changes, and an occupancy rate in French nursing homes that remains below its normative level (despite improving slightly by 1.2 points in the second half of 2023 compared with the first six months of the year). EBITDAR came out at €696 million over the year.

Attributable net profit for 2023 amounted to €1,355 million, including an extraordinary financial income of €2,850 million from the Equitization Capital Increase finalised on December 3^rd, 2023, and a €830 million charge arising from impairment tests on property, plant and equipment and intangible assets in accordance with IAS 36. These two items have no impact on the Company's cash position.

1- Refoundation Plan facilitating progress, and a new identity and corporate purpose

In 2023, the Company pressed ahead with the Refoundation Plan, which is structured around actions resolutely focused on employees and residents, achieving a number of significant results², including:

• in terms of health and safety at work, the work-related accident frequency rate fell 8 points in 2023 compared with 2021;

• the stability of our teams improved, with an increase of 3 percentage points in the proportion of staff on fixed-term contracts and a reduction of 3 percentage points in the rate of staff turnover in France compared with 2022. To make further progress, the Company has set a Group-wide reduction target of 5 percentage points by 2025 of the rate of turnover (average Group level in 2023: 29.3%);

• emeis forged constructive labour relations with renewed employee representative bodies, based on progressive values that are more in touch with events on the ground and with employees' expectations;

• 84% of countries have implemented tools to improve outreach with families;

• 72% of facilities now have a trained ethics and positive treatment correspondent;

• satisfaction indicators are at levels that reflect the ongoing commitment of the teams and the additional resources allocated from 2022 to improve the quality of care and support (satisfaction rate in 2023: 92.5%).

All these actions and the corresponding outcomes result from the Company's transformation project launched in 2022. They will be consolidated in the coming months by both the transformation program "CREATE" (standing for its key principes : "Commitment, Respect, Empowerment, Accountability, Trust, Excellence") and a CSR roadmap defined with the teams, aimed at structuring, and transforming the Company in the long term, while strengthening the many assets it has developed over the course of its 30-year history, namely the commitment of its teams, its medical expertise, its drive for innovation and portfolio of complementary activities.

On 20 March, as part of the ongoing Refoundation Plan, the Company adopted a new identity, emeis, and a new corporate purpose: "Together, let’s stand as a strength for the vulnerable among us". The new corporate name and purpose are the result of extensive consultation with employees. They demonstrate the commitment of our teams to a purpose that will enable us and our stakeholders – patients, residents, family and friends, healthcare professionals, regulators and public authorities – to respond even more effectively to the major challenges facing society in terms of mental and physical health, and old age.

In order to anchor this change of identity as a marker for sustainable transformation, the corporate purpose will be enshrined in the Company's Articles of Association, subject to a positive vote at the Annual General Meeting. The emeis Group will then embark on the process of becoming a mission-led company by 2025.

This Refoundation Plan could not be implemented without the success of the financial restructuring plan, which has ensured the Company's long-term viability and has been accompanied by the acquisition of 50.2% of the Company's share capital by new reference shareholders (Caisse des Dépôts, CNP Assurances, MAIF and MACSF³).

2- Analysis of the 2023 full-year consolidated income statement

As part of the publication of its 2023 annual results, the Group refers to financial indicators taken from its consolidated financial statements, as well as to alternative performance measures, which are presented in detail in the appendices to this press release. Definitions and calculation methods for these indicators are presented on page 10, 13 and 14 of this press release.

ORPEA SA’s consolidated revenue came to €5,198 million in 2023, up 11.0% compared with 2022, including organic growth of 9.5%. This performance was driven by an increase in Group occupancy rates (up 1.5 percentage points to 83.1% on average in 2023 and up 1.1 percentage points in the second half compared with the first half; the average occupancy rate for nursing homes in France was up 1.2 percentage points in the second half of 2023 compared with the first half), with the exception of nursing homes in France (average occupancy rate in 2023: 83.6%, vs. 85.6% in 2022). It is also attributable to an increase in capacity over the year, both as a result of the opening of 31 additional facilities and the inclusion of new facilities in the scope of consolidation, bringing the total network to 1,031 facilities at the end of December 2023 (corresponding to 93,470 beds).

Operating profitability continued to be affected by the newly implemented care and support measures, persistently high inflation in 2023 that could not be passed on through pricing changes, and an occupancy rate in French nursing homes that remained below its normative level. EBITDAR came to €696 million over the year, compared with €780 million in 2022. The EBITDAR margin stood at 13.4%, with the margin for the second half up 0.4 percentage points on the first half.

Recurring operating expense amounted to €16 million, compared with €49 million in 2022.

The operating loss came to €919 million, after taking into account non-recurring items totalling €903 million, mainly comprising:

1. Charges resulting from asset impairment tests in accordance with IAS 36 amounting to €830 million, including €438 million in respect of IFRS 16 right-of-use assets. For the impairment tests under IAS 36, in 2023 the Group adapted its method in order to move towards a post-IFRS 16 approach. It should be noted that impairment of right-of-use assets under IFRS 16 does not change the value of real estate assets held by the Company, but results in a reduction in the value of the corresponding right-of-use assets under IFRS 16, which are presented discretely in the balance sheet.

2. Non-recurring expenses related to the management of the crisis, for €74 million. This amount includes financial restructuring costs not allocated to additional paid-in capital.

Reported profit before tax came to €1,400 million, after taking into account net financial income of €2,319 million.

This includes an extraordinary financial income (with no cash and no tax impact) of +€2,850 million relating to the conversion of ORPEA S.A.'s unsecured debt for 3.8 billion euros, implemented as part of the financial restructuring.

Attributable net profit for the year came out at €1,355 million.

3- Valuation of the real estate portfolio

As of December 31^st, 2023, the estimated value of the real estate portfolio was €6.3 billion. This amount includes €5.3 billion in assets valued by the independent appraisers⁴, covering a total of 414 sites, most of which are located in France. The appraisals were based on an average real estate asset yield of 5.6%, versus 5.1% at end-2022, reflecting current conditions in the healthcare real estate market.

4- Main consolidated balance sheet, debt and liquidity indicators

The value of right-of-use assets recognised under IFRS 16 decreased from €3.5 billion at end-2022 to €3.1 billion at 31 December 2023, mainly attributable to write-off further to impairment tests conducted in accordance with the IAS 36. As the right-of-use assets relate to leased buildings, these write-offs had no impact on the value of the real estate portfolio held by the Company.

Consolidated equity is amounting to +€1.9 billion as of December 31^st, 2023, compared to a € (1.5) billion one year earlier. This recapitalization of shareholders' equity results from the two capital increases carried out in 2023 and the extraordinary financial income (with no cash and no tax impact) of €2,850 million recorded as part of the company's financial restructuring.

Financial net debt (excluding IFRS 16 lease liabilities) on December 31^st, 2023, amounted to €4.6 billion, compared to €8.8 billion one year earlier. This very sharp reduction in debt is attributable to the financial restructuring plan, which led to:

• the conversion into capital of €3.8 billion of ORPEA SA's unsecured debt following the Equitisation Capital Increase, the settlement-delivery of which took place on 3 December 2023, which resulted in the recognition of exceptional financial income of €2,850 million;

• a cash contribution following the Groupement⁵ Capital Increase of €1.2 billion, the settlement-delivery of which took place on 19 December 2023.

Following these two transactions, the company repaid €700 million in debt, corresponding to the repayment of D1A, D1B, D2 and A4 loans.

Based on pre-IFRS 16 2023 EBITDA of €204 million, the Group's financial leverage⁶ came out at 22.8x.

The third capital increase of €390 million under the financial restructuring plan was completed on 15 February 2024.

Cash and cash equivalents at the end of 2023 amounts to €645 million. The Group had an undrawn line of credit of €400 million as of December 31^st, 2023.

5- 2023 Financing Table (pre-IFRS 16)

Net recurring operating cash flow represented an outflow of €87 million, after deducting maintenance and IT investments of €141 million and other recurring operating cash flows (including changes in working capital) representing an outflow of €149 million. This includes the impact of the decision to grant employees more favourable salary settlement periods, representing an outflow of approximately €60 million.

Net cash flow before financing amounted to €746 million, breaking down as:

• €315 million in development capital expenditure, mainly in real estate (greenfield projects). The decrease of €323 million in this item versus 2022 reflects the precautionary measures taken during the year (deferrals and curtailments) designed to preserve the Group's liquidity;

• €146 million in proceeds from real estate disposals in 2023 (mainly in the Netherlands, Austria and Germany) bringing total proceeds from real estate disposals over the 2022-2023 period to around €300 million, in line with the trajectory set out in the June 2022 financing plan⁷. As a reminder, the Company has a contractual commitment to complete a total of €1.25 billion in real estate disposals⁸ by the end of 2025;

• €338 million in debt servicing costs, mainly related to the €3.2 billion in financing arranged in June 2022 with the Group's main banking partners;

• €145 million in non-recurring items, including expenses related to the management of the crisis experienced by the Group, including outflows relating to financial restructuring.

For 2023, cash flow from operating activities restated for the positive impact of IFRS 16 represented a net cash outflow of €81 million, including €145 million in non-recurring items. Cash used in investing activities net of disposal proceeds was €318 million.

6- Reforecast of 2024 and procedures launched on the 2025-2026 forecasts

The Group has finalised the reforecast of its 2024 financial performance. The Company now anticipates 2024 EBITDAR of between €800 million and €835 million, corresponding to a growth between 15% and 20% compared to 2023. The reforecasting exercise incorporates the most reasonable assumptions and estimates to date, including a Group average occupancy rate of 85.1% in the first-quarter 2024, including 83.1% for nursing homes in France.

The main adjustment on the reforecast 2024 is related to France operations, due to a less level of operational recovery than initially anticipated.

The Group has taken precautionary measures with regards to capital expenditures in order to offset the decrease expected in EBITDAR on the Group cash trajectory. The company also remains fully committed to its real estate disposal plan and is looking at every opportunity to accelerate the process.

This new forecast compares with the 2024 EBITDAR forecast of €891 million included in the documentation relating to the recent capital increases⁹.

The Group plans to begin internal work on updating its multi-year business plan in the coming months. At the end of this process, which is expected to be completed by the end of the fourth quarter of 2024, the Company will disclose, in accordance with applicable regulations, any changes in the trajectory set out in the business plan in the documentation relating to the recent capital increases, in particular concerning the Group’s financial leverage¹⁰ (as a reminder, the financial leverage included in the business plan underlying the capital increases was 5.5x by 2026).

7- Financial information and agenda

A web conference will be held by Laurent Guillot (Chief Executive Officer) and Laurent Lemaire (Chief Financial Officer) to present the Group’s 2023 results, today at 8:30 a.m (CEST). The presentation along with a recording of the web conference will be made available on the Company's website (link).

It is also possible to take part in this web conference by telephone. Login details are as follows:

• France : +33 (0) 1 7037 7166

• UK: +44 (0) 33 0551 0200

• USA: +1 786 697 3501

• Then tell the operator that you are calling for the conference ORPEA ENG

The Company expects to publish its revenue for the first quarter of 2024 on May 14^th, 2024.

DISCLAIMER

This document contains forward-looking statements that involve risks and uncertainties, including information incorporated by reference, regarding the Group’s expected growth and profitability in the future that may significantly impact the expected performance indicated in the forward-looking statements. These risks and uncertainties relate to factors that the Company cannot control or accurately estimate, such as future market conditions. Any forward-looking statements made in this document express expectations for the future and should be regarded as such. Actual events or results may differ from those described in this document due to a number of risks or uncertainties, as described in Chapter 2 of the Company's 2022 Universal Registration Document, which is available on the Company's website and on the website of the French financial markets authority (Autorité des marchés financiers) (www.amf-france.org).

About emeis

With 76,000 experts and professionals in healthcare, care, and supporting the most vulnerable among us, emeis operates in 21 countries with five core activities: psychiatric hospitals, medical care and rehabilitation clinics, nursing homes, home care services, and assisted-living facilities.

Every year, emeis welcomes 267,000 residents, patients, and other beneficiaries. emeis is committed and is taking action to rise to a major challenge facing our society, i.e., the increase in the number of people placed in vulnerable positions as a result of accidents or old age, and of cases of mental illness.

ORPEA SA, the Group's parent company, is 50.2% owned by Caisse des Dépôts, CNP Assurances, MAIF, and MACSF Epargne Retraite. It is listed on the Euronext Paris stock exchange (ISIN: FR001400NLM4) and is a member of the SBF 120 and CAC Mid 60 indices.

Website: www.emeis-group.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240416317006/en/

Contacts

Press contacts
Isabelle Herrier-Naufle
Director of Press Relations &
e-Reputation
+33 7 70 29 53 74
isabelle.herrier@emeis.com

IMAGE 7
Charlotte Le Barbier // Laurence Heilbronn
+33 6 78 37 27 60 // +33 6 89 87 61 37
clebarbier@image7.fr // lheilbronn@image7.fr

Investor Relations
Benoit Lesieur
Investor Relations Director
benoit.lesieur@emeis.com
Toll-free number for shareholders (from France only):
0 805 480 480

NEWCAP
Dusan Oresansky
+33 1 44 71 94 94
emeis@newcap.eu